Smoking in United States of America
In the United States of America, smoking is allowed but tobacco products should follow some regulations. Under these regulations, health warnings on tobacco packaging including cigarettes are mandatory, the minimum legal age for their sales is 21 years, and there are no federal legal restrictions on smoking in public places. While tobacco advertising is regulated, not all forms of their advertising are banned. An excise tax of 32.16% with a total taxation rate of 37.36% is applied on cigarettes. Cigarettes can legally be sold with authorised documents. They may also be purchased through vending machines as well as through online channels. Importing cigarettes for trade is allowed with an appropriate import license. Despite these control measures, prevalence data show that smoking remains an important public health issue in the United States. There were 39.8 million current smokers in the country in 2024. This represents an overall adult smoking prevalence of 14.1%, with higher prevalence among men (17.1%) than among women (11.1%). In comparison, the overall current smoking prevalence was 12.3% in 2022. The adult daily smoking prevalence was recorded to be 10.01% in 2020. Smoking-related mortality also remains significant in the country. In 2021, smoking resulted in 360,370 deaths, including 216,986 male deaths and 143,383 female deaths. This shows that smoking accounted for 10.38% of all deaths in the United States in 2021, with a higher rate among men (11.9%) than among women (8.7%).
Read articles from United States of America
October 06, 2026 by protectingtaxpayers.org
A Major Victory for Businesses, Vapers and Public Health
The Fifth Circuit ruled that the FDA unlawfully imposed a comparative efficacy standard on flavored vaping products without the notice-and-comment process required by the Administrative Procedure Act. The standard required manufacturers to demonstrate greater benefits for adult smokers than tobacco-flavored products, contributing to widespread marketing denials. The text argues that these barriers restrict potentially lower-risk alternatives for smokers and increase healthcare costs. It also distinguishes lack of FDA authorization from proof that a product is dangerous, noting that authorization does not establish safety. The ruling calls for lawful, transparent regulation that protects young people, allows businesses fair participation, and preserves adult access to potentially beneficial alternatives to cigarettes.
October 05, 2026 by substack.com
Rethinking Population Health Implications in an Era of Declining Cigarette Smoking
The author argues that tobacco harm reduction (THR) should extend beyond helping current smokers switch to lower-risk nicotine products. US data show stable overall nicotine use alongside declining smoking and rising vaping, particularly among young adults. The author interprets these trends as suggesting that vaping may divert some people from smoking, although population trends alone cannot establish causation. THR could therefore include switching, maintaining smoking abstinence, and preventing smoking among would-be smokers. Whether vaping benefits never-smokers depends on whether they would otherwise smoke or remain nicotine-free. The author recommends broader messaging, research, and population models examining these counterfactuals to sustain THR’s relevance as cigarette smoking declines.
October 02, 2026 by reason.com
Smoking Is Bad for You. Nicotine Isn't—but Politicians Keep Trying To Ban It.
Easthampton became Massachusetts’ 25th municipality to adopt a lifetime nicotine-sales ban for younger generations, including noncombustible products. The author argues these policies conflate nicotine with smoking’s combustion-related harms and undermine harm reduction. Nicotine is addictive and carries cardiovascular and adolescent risks, but research suggests potential cognitive benefits, though therapeutic evidence remains preliminary. Comparing nicotine with caffeine and accepted nicotine-replacement therapies, the text criticizes restrictions on adult choice and the goal of eliminating nicotine use rather than smoking-related disease. It also warns that prohibition could encourage poorly studied, potentially stronger synthetic alternatives. The author advocates distinguishing nicotine from cigarettes and weighing its risks and benefits rather than treating it as inherently unacceptable.
October 02, 2026 by cspdailynews.com
FDA’s common sense approach to tobacco regulation
The article portrays FDA tobacco director Bret Koplow as shifting regulation toward harm reduction after years of approval backlogs and limited support for cigarette alternatives. Speaking at a tobacco retailers’ conference, Koplow advocated cooperation with manufacturers and retailers to protect minors, accelerate authorization of scientifically supported lower-risk products for adults, and combat illicit e-cigarettes. His authorization of vaping and nicotine pouch products has drawn praise from industry and opposition from public health groups. Koplow emphasizes that no tobacco product is safe and quitting is healthiest, but completely switching from cigarettes to FDA-authorized, noncombustible alternatives can reduce exposure to toxic and cancer-causing chemicals.
October 02, 2026 by protectingtaxpayers.org
Science Over Stigma: Why Legislators Must Embrace Tobacco Harm Reduction
The text argues that growing evidence supports tobacco harm reduction products, especially e-cigarettes, as alternatives for adult smokers. It cites a Cochrane review of nine trials finding vaping more effective than traditional nicotine replacement therapies for quitting, with no serious harms identified in those trials. It also describes FDA authorization of reduced-risk marketing claims for ZYN nicotine pouches. The author contends that restrictive policies discourage cessation and fuel illicit markets, while cigarette smoking causes substantial mortality and economic costs. The text urges clinicians and policymakers to prioritize scientific evidence over stigma and prohibition, arguing that access to lower-risk nicotine products could improve public health.
October 01, 2026 by reason.com
The FDA Promises To Streamline the Dauntingly Complex Rules for Approving Nicotine Products
Regulatory complexity has become part of the nicotine problem. A system too slow or difficult to navigate can leave legal smoke-free products waiting while cigarettes remain on shelves and unapproved alternatives fill the gaps. Streamlining FDA approvals would not mean lowering the evidentiary bar; it would mean making science-based decisions in time to matter. Harm reduction needs a pathway that is rigorous, workable and capable of bringing responsible products into the legal market.
September 30, 2026 by clearingtheair.eu
Researchers challenge Irish PM’s vaping claim
A claim from the top of government can shape what thousands of smokers believe about risk. Describing vaping and cigarettes in a way that blurs their differences does not protect public health; it can make lower-risk choices look pointless. Researchers challenging the Irish PM’s statement should be taken seriously because risk communication has consequences. Political messages on nicotine need to be accurate, proportionate and clear about the far greater harms of combustion.
September 30, 2026 by clivebates.com
Think carefully before you sign this letter...
A signature can turn uncertainty into authority. That is why public health statements on nicotine deserve careful reading before names are added to them. Claims about vaping, pouches or other smoke-free products can influence policy, clinical advice and the choices smokers believe are available. Experts should sign only what reflects the evidence clearly — including the difference between nicotine use and the far greater harms of combustion.
September 29, 2026 by 2firsts.com
Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
The risk continuum should be central to tobacco policy because not all nicotine products carry the same harm. Cigarettes sit at the highest end because they burn tobacco, while smoke-free alternatives can reduce exposure for adults who switch completely. That distinction is not a technical detail; it is the basis for proportionate regulation, honest communication and better choices for smokers. Tobacco policy becomes more effective when it reflects levels of risk instead of treating nicotine as one category.
September 29, 2026 by 2firsts.com
Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
The risk continuum should be central to tobacco policy because not all nicotine products carry the same harm. Cigarettes sit at the highest end because they burn tobacco, while smoke-free alternatives can reduce exposure for adults who switch completely. That distinction is not a technical detail; it is the basis for proportionate regulation, honest communication and better choices for smokers. Tobacco policy becomes more effective when it reflects levels of risk instead of treating nicotine as one category.